Related Experiment Video

Updated: Apr 7, 2026

High-throughput Measurement of Gut Transit Time Using Larval Zebrafish
06:48

High-throughput Measurement of Gut Transit Time Using Larval Zebrafish

Published on: October 23, 2018

8.1K

Pharmacokinetic study of metopimazine by oral route in children

Eric Mallet1, Frederic Bounoure2, Mohamed Skiba2

  • 1CIC INSERM 204, Department of Pediatrics, Rouen University Hospital Charles Nicolle, 76031, Rouen, France.

Pharmacology Research & Perspectives
|July 15, 2015
PubMed

Insights

Metopimazine (MPZ), an antiemetic, was studied in children for the first time. Pharmacokinetics in children were similar to adults, confirming the 0.33 mg/kg dosage for effective antiemetic treatment.

Area of Science:

  • Pharmacology
  • Pediatric Medicine
  • Drug Metabolism

Background:

  • Metopimazine (MPZ) is a well-tolerated antiemetic widely used in France.
  • Pediatric pharmacokinetics of MPZ have not been previously established.
  • Endocrine testing often involves stimuli with emetic potential.

Purpose of the Study:

  • To determine the pharmacokinetics of Metopimazine (MPZ) in children.
  • To evaluate the safety and efficacy of MPZ as an antiemetic in a pediatric population undergoing endocrine testing.

Main Methods:

  • Oral administration of a single 0.33 mg/kg dose of MPZ to 8 children.
  • Utilized residual sera from human Growth Hormone (hGH) stimulation tests.
  • Quantified MPZ and its metabolite AMPZ using HPLC-MS/MS over 270 minutes.

Main Results:

  • MPZ exhibited rapid absorption (median Cmax 17.2 ng/mL at 1 hour) with a half-life of 2.18 hours.
  • The active metabolite AMPZ showed higher concentrations (median Cmax 76.3 ng/mL) and prolonged presence.
  • Pediatric pharmacokinetic profiles were comparable to adult data, with no adverse effects reported.

Conclusions:

  • The study confirms the pharmacokinetic profile of Metopimazine in children is similar to adults.
  • The established dosage of 0.33 mg/kg is appropriate for children under 15 kg, up to three times daily.
  • MPZ demonstrates good tolerance and efficacy as an antiemetic in pediatric patients.
Keywords:
Antiemetic drugchildrenmetopimazinepharmacokinetics

More Related Videos

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

8.9K
Microsurgical Skills of Establishing Permanent Jugular Vein Cannulation in Rats for Serial Blood Sampling of Orally Administered Drug08:28

Microsurgical Skills of Establishing Permanent Jugular Vein Cannulation in Rats for Serial Blood Sampling of Orally Administered Drug

Published on: December 14, 2021

10.8K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
341
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
762
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
484
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
378
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
817
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
887